Phase I trial of PCNU

L. A. Kalman, R. J. Gralla, E. S. Casper, M. G. Kris, C. Gordon, T. M. Woodcock

Research output: Contribution to journalArticlepeer-review


In a phase I trial, 28 patients with advanced solid tumors were given PCNU daily for 5 days by iv infusion over 20 minutes at 6-week intervals. The total dose for each course ranged from 25 to 150 mg/m2 in six escalation steps. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of ≥ 82.5 mg/m2. Leukopenia occurred only at higher doses. Nausea was uncommon, and vomiting did not occur. There were no adverse drug-related effects on renal or hepatic function. No antitumor activity was observed. A dose range of 100-125 mg/m2 iv for each 5-day course (20-25 mg/m2/day) is recommended for phase II studies.

Original languageEnglish (US)
Pages (from-to)1027-1029
Number of pages3
JournalCancer Treatment Reports
Issue number11
StatePublished - Dec 1 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase I trial of PCNU'. Together they form a unique fingerprint.

Cite this